Salma Jabbour, MD, on Future Trials in Stage III NSCLC

Video

CancerNetwork® sat down with Salma Jabbour, MD, of Rutgers Cancer Institute, at 2021 ASCO to talk about what she believed was the most interesting and impactful study to come out of the meeting.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Salma Jabbour, MD, to discuss her thoughts about the phase 2 KEYNOTE-799 trial (NCT03631784). This study examined pembrolizumab (Keytruda) in combination with platinum-doublet chemotherapy and radiation in patients with unresectable, stage III non–small cell lung cancer (NSCLC).

Results of the trial indicated that the treatment regimen for this population of patients demonstrated promising antitumor activity across patient subgroups regardless of PD-L1 expression and tumor histology. In a group of patients with mixed histology who were treated with pembrolizumab plus carboplatin/paclitaxel, the overall response rate was 70.5% (95% CI, 61.2%-78.8%), with more than three-quarters of patients having a response duration longer than 1 year.

Transcript:

I’m, excited about KEYNOTE-799. I do think that this will open the door for many future trials, and much excitement in the stage III setting. I am excited to continue to hear further results about stage III lung cancers.

Reference

Jabbour SK, KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.

Recent Videos
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
4 experts in this video
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content